Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction.
Adenocarcinomas of the esophagogastric junction
Mean platelet volume
Neoadjuvant treatment
Platelet count
Primary resection
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
06 Sep 2023
06 Sep 2023
Historique:
received:
26
05
2023
accepted:
01
09
2023
medline:
8
9
2023
pubmed:
7
9
2023
entrez:
6
9
2023
Statut:
epublish
Résumé
The aim of this study was to investigate the prognostic role of plasma platelet count (PLT), mean platelet volume (MPV), and the combined COP-MPV score in patients with resectable adenocarcinomas of the gastroesophageal junction. Platelet activation, quantified by PLT and elevated MPV, plays an essential part in the biological process of carcinogenesis and metastasis. An increased preoperative COP-MPV is associated with poor survival in various tumor entities. Data of 265 patients undergoing surgical resection for adenocarcinoma of the gastroesophageal junction were abstracted. COP-MPV score was defined for each patient. Utilizing univariate and multivariate Cox proportional hazard analyses, survival was determined. In univariate analysis, elevated PLT (HR 3.58, 95% CI 2.61-4.80, p<0.001) and increased COP-MPV (HR 0.27, 95% CI 0.17-0.42, p<0.001 and HR 0.42, 95% CI 0.29-0.60, p<0.001) significantly correlated with shorter patients' overall and disease-free survival, for all 256 patients, as well as in the subgroups of neoadjuvantly treated (p<0.001) and primarily resected patients (p<0.001). COP-MPV remained a significant prognostic factor in multivariate analysis for OS. However, PLT alone showed significant diminished OS and DFS in all subgroups (p<0.001) in univariate and multivariate analysis. PLT is a potent independent prognostic biomarker for survival in a large prospective cohort of patients with resectable adenocarcinoma of the gastroesophageal junction. Additionally, we confirm that the COP-MPV score is significantly associated with worse outcome in these patients, but has no benefit in comparison to PLT.
Sections du résumé
OBJECTIVE
OBJECTIVE
The aim of this study was to investigate the prognostic role of plasma platelet count (PLT), mean platelet volume (MPV), and the combined COP-MPV score in patients with resectable adenocarcinomas of the gastroesophageal junction.
BACKGROUND
BACKGROUND
Platelet activation, quantified by PLT and elevated MPV, plays an essential part in the biological process of carcinogenesis and metastasis. An increased preoperative COP-MPV is associated with poor survival in various tumor entities.
METHODS
METHODS
Data of 265 patients undergoing surgical resection for adenocarcinoma of the gastroesophageal junction were abstracted. COP-MPV score was defined for each patient. Utilizing univariate and multivariate Cox proportional hazard analyses, survival was determined.
RESULTS
RESULTS
In univariate analysis, elevated PLT (HR 3.58, 95% CI 2.61-4.80, p<0.001) and increased COP-MPV (HR 0.27, 95% CI 0.17-0.42, p<0.001 and HR 0.42, 95% CI 0.29-0.60, p<0.001) significantly correlated with shorter patients' overall and disease-free survival, for all 256 patients, as well as in the subgroups of neoadjuvantly treated (p<0.001) and primarily resected patients (p<0.001). COP-MPV remained a significant prognostic factor in multivariate analysis for OS. However, PLT alone showed significant diminished OS and DFS in all subgroups (p<0.001) in univariate and multivariate analysis.
CONCLUSION
CONCLUSIONS
PLT is a potent independent prognostic biomarker for survival in a large prospective cohort of patients with resectable adenocarcinoma of the gastroesophageal junction. Additionally, we confirm that the COP-MPV score is significantly associated with worse outcome in these patients, but has no benefit in comparison to PLT.
Identifiants
pubmed: 37673810
doi: 10.1007/s00423-023-03093-y
pii: 10.1007/s00423-023-03093-y
pmc: PMC10482770
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
351Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2017 Nov 25;390(10110):2383-2396
pubmed: 28648400
Tumour Biol. 2016 Jul;37(7):9323-31
pubmed: 26779631
Int J Lab Hematol. 2008 Jun;30(3):214-9
pubmed: 18479300
Thromb Res. 2016 Mar;139:65-76
pubmed: 26916298
Cells. 2020 Apr 01;9(4):
pubmed: 32244723
Lancet Oncol. 2002 Jan;3(1):27-34
pubmed: 11908507
Oncotarget. 2018 Jan 8;9(6):6968-6976
pubmed: 29467943
Front Genet. 2022 Sep 14;13:965033
pubmed: 36186426
Semin Oncol. 2014 Jun;41(3):302-10
pubmed: 25023346
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Blood Coagul Fibrinolysis. 1996 Mar;7(2):157-61
pubmed: 8735807
J Am Coll Surg. 2004 May;198(5):737-41
pubmed: 15110807
J Thorac Oncol. 2017 Jan;12(1):36-42
pubmed: 27810391
Ann Surg. 2021 Mar 1;273(3):532-541
pubmed: 31425286
Comput Struct Biotechnol J. 2023 Apr 15;21:2873-2883
pubmed: 37206616
Nat Rev Cancer. 2011 Feb;11(2):123-34
pubmed: 21258396
Oncology. 2000 Feb;58(2):169-74
pubmed: 10705245
J Hematol Oncol. 2018 Oct 11;11(1):125
pubmed: 30305116
Semin Thromb Hemost. 2014 Apr;40(3):296-305
pubmed: 24590421
Sci Rep. 2020 Nov 9;10(1):19296
pubmed: 33168847
Neoplasma. 2010;57(2):145-50
pubmed: 20099978
Haematologica. 1989 Nov-Dec;74(6):541-5
pubmed: 2628235
Ann Surg Oncol. 2019 Apr;26(4):976-985
pubmed: 30706229
Cancer Prev Res (Phila). 2008 Nov;1(6):393-5
pubmed: 19138984
Semin Thromb Hemost. 2004 Feb;30(1):95-108
pubmed: 15034801
Am J Physiol Cell Physiol. 2019 Feb 1;316(2):C264-C273
pubmed: 30462538
Eur J Intern Med. 2011 Dec;22(6):e95-8
pubmed: 22075321
Am J Gastroenterol. 2017 Aug;112(8):1247-1255
pubmed: 28585555
Oncotarget. 2017 Feb 28;8(9):15632-15641
pubmed: 28152504
Cancer Res. 2020 Jan 15;80(2):291-303
pubmed: 31727628
Gan To Kagaku Ryoho. 2015 Nov;42(12):1980-2
pubmed: 26805237
N Engl J Med. 2012 Feb 16;366(7):610-8
pubmed: 22335738
Lancet Oncol. 2004 Nov;5(11):655-63
pubmed: 15522652
Eur Heart J. 2001 Sep;22(17):1561-71
pubmed: 11492985
Nat Commun. 2014 Oct 28;5:5256
pubmed: 25348021
Anticancer Res. 2005 Mar-Apr;25(2A):709-13
pubmed: 15868900
J Clin Lab Anal. 2020 Aug;34(8):e23320
pubmed: 32233046
Thromb Res. 2014 May;133 Suppl 2:S149-57
pubmed: 24862136
J Surg Res. 2019 Oct;242:296-303
pubmed: 31125843
Mol Clin Oncol. 2019 Apr;10(4):457-462
pubmed: 30931118
Br J Surg. 1998 Nov;85(11):1457-9
pubmed: 9823902
Lancet Oncol. 2002 Jul;3(7):425-30
pubmed: 12142172
Arq Bras Cardiol. 2006 Oct;87(4):446-50
pubmed: 17128313
N Engl J Med. 1986 Oct 16;315(16):983-9
pubmed: 3531859
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
CA Cancer J Clin. 2017 Jul 8;67(4):304-317
pubmed: 28556024
J Korean Assoc Oral Maxillofac Surg. 2017 Oct;43(5):305-311
pubmed: 29142864
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
J Gastrointest Cancer. 2013 Sep;44(3):293-304
pubmed: 23549858
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686